Has Rosemary Ouseph, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,448 in general payments to Rosemary Ouseph, MD across 34 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rosemary Ouseph, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rosemary Ouseph, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rosemary Ouseph, MD

Nephrology · Louisville, KYNPI 1740261783

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.1% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.

$3,448in general payments, 2019–2025

Across 34 payments — averaging $101.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Veloxis Pharmaceuticals, Inc.$487
Mallinckrodt Hospital Products Inc.$365
Vifor Pharma, Inc.$352
Calliditas Therapeutics US Inc.$338
Bayer$242
Scpharmaceuticals Inc.$239
plus $1K from 10 others

$750in research payments, 2019–2025

Across 1 payment — averaging $750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$750

What the payments were for

Food & beverage$3,34897%
Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Veloxis Pharmaceuticals, Inc.	4	$487
Mallinckrodt Hospital Products Inc.	4	$365
Vifor Pharma, Inc.	3	$352
Calliditas Therapeutics US Inc.	3	$338
Bayer	2	$242
Scpharmaceuticals Inc.	2	$239
Takeda Pharmaceuticals U.S.A., Inc.	2	$235
Baxter Healthcare	3	$221
Travere Therapeutics, Inc.	2	$218
Merck	2	$133
Mallinckrodt Enterprises LLC	1	$125
AbbVie	1	$122
Nxstage Medical, Inc.	2	$120
AstraZeneca	1	$120
Sanofi	1	$113
Otsuka America Pharmaceutical, Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,448 in reported general payments places this provider in the 70th percentile of 165 nephrology providers in Kentucky.

See all nephrology providers in Kentucky →

Medicare billing

Part B allowed, 2024

$92,977

Medicare patients

273

Services billed

904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
NulojixBelatacept	12	$23,254
Everolimus	13	$22,956
EliquisApixaban	16	$9,244
Mycophenolic AcidMycophenolate Sodium	15	$5,511
Cinacalcet Hcl	19	$3,412
Tacrolimus	29	$1,477
NitrofurantoinNitrofurantoin Macrocrystal	13	$374
Lactated RingersRinger's Solution,lactated	12	$370
K-Phos OriginalPotassium Phosphate,monobasic	13	$366
Metoprolol Tartrate	18	$354
Prednisone	76	$315
Potassium Chloride	15	$279
Bumetanide	15	$279
Losartan Potassium	58	$279
Hydralazine Hcl	25	$220

Paid to pharmacies, not to this prescriber.

Other nephrology in Louisville

Danny WooLouisville$427K
Dawn CasterLouisville$193K
Nizar AttallahLouisville$113K
Shafic Abdul Wahab El HindiLouisville$45K
George AronoffLouisville$26K
Jai BhimaniLouisville$10K
Alexander AfanasyevLouisville$10K
William DuffLouisville$9K
Bhagwan BhimaniLouisville$7K
Aziz ChamiLouisville$6K

See the full list for Kentucky →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →